All Press Releases for August 04, 2021

Vagus Nerve Stimulation Shows Promise Battling COVID-19

Transcutaneous vagus nerve stimulation (tVNS) was associated with reduced mechanical ventilation and death.

"The surging COVID-19 Delta Variant and low vaccination rates across the globe demand innovative, effective, life-saving therapies such as vagus nerve stimulation." – Dr. Patrick Nemechek

    OVERLAND PARK, KS, August 04, 2021 /24-7PressRelease/ -- Nemechek Technologies, LLC is proud to announce that Dr. Patrick Nemechek's peer-reviewed article "Transcutaneous Vagus Nerve Stimulation is Associated with Lower Mechanical Ventilation and Mortality in COVID-19 Patients" study was published last month in the Journal of Emerging Diseases and Virology.

The study of hospitalized COVID-19 patients was conducted at Hospital Zonal Virgen Del Carmen in Zarate, Buenos Aires, Argentina. 51 patients requiring oxygen on admission received transcutaneous vagus nerve stimulation for 5 minutes 2-4 times per day using Nemechek Technologies' Vitality Smartcable® neuromodulation device.

Stimulation of the vagus nerve activates a response called the inflammatory reflex which enables the body's natural regulation of damaging inflammation, including the deadly hyper-immune response known as a cytokine storm. The storm is a massive release of inflammatory molecules associated with acute respiratory distress syndrome (ARDS) resulting in many COVID-19 fatalities.

Study findings were remarkable with mechanical ventilation and mortality rates less than almost all other published large COVID-19 cohorts. The survival rate for the 51 study participants was 82.4% with only 3.4% of the survivors receiving mechanical ventilation. The study cohort included patients with the typical distribution of pre-existing comorbidities.

Dr. Nemechek previously released a video presenting the final data from the study of patients who received transcutaneous vagus nerve stimulation in addition to the standard of care for all COVID-19 patients at the hospital.

Watch Dr. Nemechek's video (10 minutes)

Read the peer-reviewed article

Last month, Nemechek Technologies' CEO, Dr. Patrick Nemechek, was awarded his 2nd US Patent. Entitled "Methods of Treating COVID-19 Induced Cytokine Storm", it explains the use of transcutaneous vagus nerve stimulation (tVNS) to treat patients with COVID pneumonia. An earlier patent on his method of reversing autonomic nervous system damage is widely known as "The Nemechek Protocol®". The Nemechek Protocol includes the use of vagus nerve stimulation to lower systemic inflammation. Dr. Nemechek has treated more than 1,000 patients with vagus nerve stimulation therapy over the past ten years at his clinic in Buckeye, Ariz.

Nemechek Technologies manufactures and distributes the Vitality Smartcable neuromodulator, the only such device to be powered and operated by a smartphone.

# # #

Contact Information

Mike Nemechek
Nemechek Technologies, LLC
Overland Park, KS
United States
Voice: 913-219-1239
E-Mail: Email Us Here
Website: Visit Our Website
Follow Us: